Edition:
India

Akorn Inc (AKRX.O)

AKRX.O on Nasdaq

3.84USD
19 Jul 2019
Change (% chg)

$-0.03 (-0.78%)
Prev Close
$3.87
Open
$3.87
Day's High
$3.97
Day's Low
$3.77
Volume
858,997
Avg. Vol
2,404,119
52-wk High
$19.65
52-wk Low
$2.64

About

Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $4,101.01
Shares Outstanding(Mil.): 124.92
Dividend: --
Yield (%): --

Financials

  AKRX.O Industry Sector
P/E (TTM): 33.22 29.88 32.66
EPS (TTM): 0.99 -- --
ROI: 6.80 14.90 14.49
ROE: 14.90 16.02 15.79

Akorn gets FDA warning letter for another manufacturing plant

Akorn Inc said on Tuesday it received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker.

25 Jun 2019

Akorn gets FDA warning letter for another manufacturing plant

Akorn Inc said on Tuesday it received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker.

25 Jun 2019

UPDATE 3-Akorn gets FDA warning letter for another manufacturing plant

June 25 Akorn Inc said on Tuesday it received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker.

25 Jun 2019

Akorn gets FDA's warning letter related to New Jersey manufacturing plant

June 25 Akorn Inc said on Tuesday the U.S. Food and Drug Administration has raised certain issues related to the inspection of its Somerset, New Jersey manufacturing facility in July and August of 2018.

25 Jun 2019

FDA flags concerns at Akorn's Amityville plant, shares slip

Generic drugmaker Akorn Inc said on Thursday the U.S. Food and Drug Administration had raised concerns about its manufacturing plant in Amityville, New York, that included a lack of records on the maintenance and cleaning of equipment.

28 Feb 2019

UPDATE 2-FDA flags concerns at Akorn's Amityville plant, shares slip

Feb 28 Generic drugmaker Akorn Inc said on Thursday the U.S. Food and Drug Administration had raised concerns about its manufacturing plant in Amityville, New York, that included a lack of records on the maintenance and cleaning of equipment.

28 Feb 2019

FDA flags sanitation concerns at Akorn's Amityville plant

Feb 28 Akorn Inc said on Thursday the U.S. Food and Drug Administration issued observations related to inspection of the company's manufacturing facility in Amityville, New York.

28 Feb 2019

Earnings vs. Estimates